First US leukemia patient dosed with Smart Immune’s investigational SMART101 cell therapy
![Smart Immune logo](https://nationalstemcelltherapy.com/wp-content/uploads/2023/01/SmartImmune-Logo-1024x576.png)
Smart Immune SAS, a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T-cell therapy platform to fully and rapidly re-arm the immune system, announced today that the first adult leukemia patient has been dosed with SMART101, a T-cell progenitor cell injection derived from donor stem cells using ProTcell at Memorial Sloan Kettering Cancer Center (MSK). The Phase […]